Reported Earnings • Apr 26
Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024) Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.59m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Duyuru • Apr 08
Corline Biomedical AB, Annual General Meeting, May 12, 2026 Corline Biomedical AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: premises of advokatfirman lindahl, vaksalagatan 10, uppsala Sweden Recent Insider Transactions • Feb 20
Chief Executive Officer recently bought kr145k worth of stock On the 17th of February, Henrik Nittmar bought around 10k shares on-market at roughly kr14.54 per share. This transaction amounted to 1.6% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Henrik has been a buyer over the last 12 months, purchasing a net total of kr377k worth in shares. Reported Earnings • Feb 19
Full year 2025 earnings released: kr0.59 loss per share (vs kr1.06 loss in FY 2024) Full year 2025 results: kr0.59 loss per share (improved from kr1.06 loss in FY 2024). Revenue: kr8.62m (down 50% from FY 2024). Net loss: kr14.7m (loss narrowed 37% from FY 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Price Target Changed • Feb 18
Price target decreased by 12% to kr29.00 Down from kr33.00, the current price target is provided by 1 analyst. New target price is 90% above last closing price of kr15.30. Stock is up 46% over the past year. The company posted a net loss per share of kr1.06 last year. New Risk • Jan 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Revenue is less than US$1m (kr8.9m revenue, or US$963k). Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (kr466.2m market cap, or US$50.5m). Reported Earnings • Nov 19
Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.14 loss in 3Q 2024) Third quarter 2025 results: kr0.14 loss per share. Revenue: kr1.61m (down 41% from 3Q 2024). Net loss: kr3.36m (loss widened 12% from 3Q 2024). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Pharmaceuticals industry in Sweden. Price Target Changed • Sep 02
Price target increased by 14% to kr21.00 Up from kr18.50, the current price target is provided by 1 analyst. New target price is 48% above last closing price of kr14.20. Stock is up 61% over the past year. The company posted a net loss per share of kr1.06 last year. Reported Earnings • Aug 27
Second quarter 2025 earnings released: kr0.13 loss per share (vs kr0.20 loss in 2Q 2024) Second quarter 2025 results: kr0.13 loss per share (improved from kr0.20 loss in 2Q 2024). Revenue: kr2.63m (down 60% from 2Q 2024). Net loss: kr3.26m (loss narrowed 26% from 2Q 2024). Revenue is forecast to grow 55% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 119 percentage points per year, which is a significant difference in performance. New Risk • Aug 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr23m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Minor Risks Revenue is less than US$5m (kr14m revenue, or US$1.4m). Market cap is less than US$100m (kr315.9m market cap, or US$32.7m). Reported Earnings • May 09
First quarter 2025 earnings released: kr0.13 loss per share (vs kr0.078 loss in 1Q 2024) First quarter 2025 results: kr0.13 loss per share (further deteriorated from kr0.078 loss in 1Q 2024). Revenue: kr2.23m (down 60% from 1Q 2024). Net loss: kr3.07m (loss widened 84% from 1Q 2024). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 88 percentage points per year, which is a significant difference in performance. Duyuru • Apr 10
Corline Biomedical AB, Annual General Meeting, May 15, 2025 Corline Biomedical AB, Annual General Meeting, May 15, 2025, at 10:00 W. Europe Standard Time. Location: at the premises of advokatfirman lindahl, vaksalagatan 10 in uppsala, uppsala Sweden Reported Earnings • Feb 18
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: kr1.06 loss per share (further deteriorated from kr0.084 loss in FY 2023). Revenue: kr17.7m (down 50% from FY 2023). Net loss: kr23.2m (loss widened kr21.4m from FY 2023). Revenue missed analyst estimates by 30%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Non-Executive Director Tomas Lifvendahl was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Nov 08
Third quarter 2024 earnings released: kr0.14 loss per share (vs kr0.008 profit in 3Q 2023) Third quarter 2024 results: kr0.14 loss per share (down from kr0.008 profit in 3Q 2023). Revenue: kr2.76m (down 66% from 3Q 2023). Net loss: kr3.00m (down kr3.18m from profit in 3Q 2023). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 25
Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.11 loss in 2Q 2023) Second quarter 2024 results: kr0.20 loss per share (further deteriorated from kr0.11 loss in 2Q 2023). Revenue: kr6.55m (down 24% from 2Q 2023). Net loss: kr4.37m (loss widened 82% from 2Q 2023). Revenue is forecast to grow 77% p.a. on average during the next 3 years, compared to a 39% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • May 05
First quarter 2024 earnings released: kr0.078 loss per share (vs kr0.047 profit in 1Q 2023) First quarter 2024 results: kr0.078 loss per share (down from kr0.047 profit in 1Q 2023). Revenue: kr5.64m (down 45% from 1Q 2023). Net loss: kr1.67m (down 264% from profit in 1Q 2023). Revenue is forecast to grow 68% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • May 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr9.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr9.7m free cash flow). Minor Risks Revenue is less than US$5m (kr36m revenue, or US$3.3m). Market cap is less than US$100m (kr226.7m market cap, or US$20.9m). Reported Earnings • Feb 16
Full year 2023 earnings released: kr0.084 loss per share (vs kr0.11 profit in FY 2022) Full year 2023 results: kr0.084 loss per share (down from kr0.11 profit in FY 2022). Revenue: kr35.9m (up 10% from FY 2022). Net loss: kr1.81m (down 178% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Duyuru • Nov 03
Corline Biomedical AB to Report Q1, 2024 Results on Apr 30, 2024 Corline Biomedical AB announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Aug 28
Second quarter 2023 earnings released: kr0.11 loss per share (vs kr0.041 profit in 2Q 2022) Second quarter 2023 results: kr0.11 loss per share (down from kr0.041 profit in 2Q 2022). Revenue: kr8.60m (up 20% from 2Q 2022). Net loss: kr2.41m (down 375% from profit in 2Q 2022). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • Jul 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (30% accrual ratio). Minor Risks Revenue is less than US$5m (kr38m revenue, or US$3.5m). Market cap is less than US$100m (kr306.2m market cap, or US$28.3m). Price Target Changed • Jun 30
Price target increased by 30% to kr39.00 Up from kr30.00, the current price target is provided by 1 analyst. New target price is 174% above last closing price of kr14.25. Stock is up 46% over the past year. The company is forecast to post a net loss per share of kr0.03 compared to earnings per share of kr0.11 last year. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to kr13.75, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years. Reported Earnings • Apr 18
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: EPS: kr0.11 (up from kr0.34 loss in FY 2021). Revenue: kr32.6m (up 90% from FY 2021). Net income: kr2.33m (up kr9.25m from FY 2021). Profit margin: 7.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 27
Third quarter 2022 earnings released: EPS: kr0.091 (vs kr0.097 loss in 3Q 2021) Third quarter 2022 results: EPS: kr0.091 (up from kr0.097 loss in 3Q 2021). Revenue: kr11.0m (up 275% from 3Q 2021). Net income: kr1.97m (up kr4.04m from 3Q 2021). Profit margin: 18% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 28
Second quarter 2022 earnings released: EPS: kr0.041 (vs kr0.10 loss in 2Q 2021) Second quarter 2022 results: EPS: kr0.041 (up from kr0.10 loss in 2Q 2021). Revenue: kr7.31m (up 117% from 2Q 2021). Net income: kr875.0k (up kr3.03m from 2Q 2021). Profit margin: 12% (up from net loss in 2Q 2021). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 39%, compared to a 90% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Breakeven Date Change • May 19
Forecast breakeven date pushed back to 2024 The analyst covering Corline Biomedical previously expected the company to break even in 2023. New forecast suggests losses will reduce by 46% per year to 2023. The company is expected to make a profit of kr116.0m in 2024. Average annual earnings growth of 119% is required to achieve expected profit on schedule. Reported Earnings • May 16
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: kr0.04 loss per share (up from kr0.08 loss in 1Q 2021). Revenue: kr4.53m (up 65% from 1Q 2021). Net loss: kr852.0k (loss narrowed 39% from 1Q 2021). Revenue exceeded analyst estimates by 41%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 168%, compared to a 95% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 28
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Third quarter 2021 results: kr0.097 loss per share (up from kr0.13 loss in 3Q 2020). Revenue: kr2.92m (up 97% from 3Q 2020). Net loss: kr2.08m (loss narrowed 3.4% from 3Q 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 6.4%, compared to a 117% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 27
Second quarter 2021 earnings released: kr0.10 loss per share (vs kr0.15 loss in 2Q 2020) The company reported a decent second quarter result with reduced losses and improved control over expenses, although revenues were weaker. Second quarter 2021 results: Revenue: kr3.37m (down 11% from 2Q 2020). Net loss: kr2.15m (loss narrowed 16% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Reported Earnings • May 16
First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.15 loss in 1Q 2020) The company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were weaker. First quarter 2021 results: Revenue: kr2.76m (down 36% from 1Q 2020). Net loss: kr1.41m (loss narrowed 44% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 7% per year, which means it is performing significantly worse than earnings. Duyuru • Apr 01
Corline Biomedical AB announced that it has received SEK 35.475 million in funding from M2 Asset Management AB (publ), HealthInvest Partners AB, and other investors Corline Biomedical AB (OM:CLBIO) announced that it has issued 3,300,000 shares at issue price of SEK 10.75 per share for gross proceeds of SEK 35,475,000 on March 30, 2021. The transaction included participation from Swedish institutional investors including new investor, M2 Asset Management AB (publ) and returning investor, HealthInvest Partners AB. Reported Earnings • Feb 28
Full year 2020 earnings released: kr0.44 loss per share (vs kr0.59 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr15.1m (up 27% from FY 2019). Net loss: kr7.29m (loss narrowed 24% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 15
New 90-day low: kr13.80 The company is down 13% from its price of kr15.95 on 17 November 2020. The Swedish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 13
New 90-day low: kr13.85 The company is down 17% from its price of kr16.65 on 14 October 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Duyuru • Dec 19
Corline Biomedical AB, Annual General Meeting, May 14, 2021 Corline Biomedical AB, Annual General Meeting, May 14, 2021. Is New 90 Day High Low • Dec 01
New 90-day low: kr15.10 The company is down 8.0% from its price of kr16.35 on 02 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Reported Earnings • Nov 28
Third quarter 2020 earnings released: kr0.13 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: kr1.49m (down 31% from 3Q 2019). Net loss: kr2.15m (loss widened 11% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Duyuru • Aug 30
Corline Biomedical AB to Report Q4, 2020 Results on Jan 26, 2021 Corline Biomedical AB announced that they will report Q4, 2020 results on Jan 26, 2021 